Velkommen til

Dansk Selskab for
Klinisk Cannabismedicin

Hvem er vi

Dansk selskab for Klinisk Cannabismedicin


Dansk Selskab for Klinisk Cannabismedicin (DSKCan) blev i 2022 stiftet som del af Lægevidenskabelige Selskaber under Lægeforeningen med det formål at afsøge mulighederne for anvendelse af cannabismedicin i patientbehandlingen og fremme evidensbaseret klinisk forskning inden for området.

Nyeste viden

Se mere
  • 11 okt
    Original: BMJ Ment Health .

    Dose-dependent effects of oral cannabidiol and delta-9-tetrahydrocannabinol on serum anandamide and related N-acylethanolamines in healthy volunteers

    Background: The mental health benefits of cannabidiol (CBD) are promising but can be inconsistent, in part due to challenges in defining an individual’s effective dosage. In schizophrenia, alterations in anandamide (AEA) concentrations, an endocannabinoid (eCB) agonist of the eCB system, reflect positively on treatment with CBD. Here, we expanded this assessment to include eCBs alongside AEA […]

    Læs mere
  • 11 okt
    Original: Cannabis Cannabinoid Res .

    Chronic Effects of Oral Cannabidiol Delivery on 24-h Ambulatory Blood Pressure in Patients with Hypertension (HYPER-H21-4): A Randomized, Placebo-Controlled, and Crossover Study

    Background: Recent data indicate that cannabidiol (CBD), a nonintoxicating constituent of cannabis, is involved in several aspects of cardiovascular regulation, including blood pressure (BP). However, the impact of chronic CBD administration on 24-h BP and vascular health has not been previously examined in patients with hypertension. The primary aim of this randomized, triple-blind, placebo-controlled, and crossover […]

    Læs mere
  • 11 okt
    Original: European Journal of Neurology

    Circulating endocannabinoidome signatures of disease activity in amyotrophic lateral sclerosis

    Background and purpose Preclinical studies of amyotrophic lateral sclerosis (ALS) have shown altered endocannabinoid (eCB) signalling that may contribute to the disease. Results from human studies are sparse and inconclusive. The aim of this study was to determine the association between serum levels of eCBs or their congeners, the so-called endocannabinoidome, and disease status and […]

    Læs mere
  • 11 okt
    Original: Addiction Biology

    Examining the moderating role of cannabis use on the relationship between alcohol consumption and inflammation in individuals with alcohol use disorder

    Inflammation appears to be a critical mechanism in the development of alcohol use disorder (AUD) and a consequence of chronic alcohol use. The potential anti-inflammatory properties of cannabis may modulate the proinflammatory effects of alcohol. This study sought to extend previous work investigating the relationship between alcohol consumption, cannabis use and circulating interleukin (IL)-6 levels […]

    Læs mere